Set against the backdrop of a streamlined therapeutic focus, GlaxoSmithKline faced a challenging Q1 in the US respiratory segment despite its market-leading position in the asthma and chronic obstructive pulmonary disease (COPD) fields.
ViewPoints: Streamlined and refocused, but GlaxoSmithKline needs respiratory portfolio to deliver.
Quarterly sales of its established ICS/LABA combination Advair declined significantly due to its exclusion from some preferred formulary listings and increased rebating from AstraZeneca (which markets the competing Symbicort brand; Spotlight On: Q1 results provide first glimpse of success for US formulary blocking tactics). Furthermore, GlaxoSmithKline's newer once-daily ICS/LABA product – Breo Ellipta – failed to gain notable traction in Q1 with management citing Medicare Part D reimbursement coverage as the primary barrier to uptake.
Investors – and competitors in the asthma and COPD markets – will therefore be watching closely as GlaxoSmithKline launches Anoro Ellipta, its first-to-market LABA/LAMA combination. Although the launch of Breo has underwhelmed, will it provide valuable lessons for GlaxoSmithKline and is Anoro likely to enjoy a faster rate of adoption as it is differentiated more greatly from Advair?
Reasons to Purchase
Set against this backdrop FirstWord is polling 100 US-based pulmonologists this week to determine...
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook